Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI.

Doo KW, Sung DJ, Park BJ, Kim MJ, Cho SB, Oh YW, Ko YH, Yang KS.

Eur Radiol. 2012 Aug;22(8):1812-9. doi: 10.1007/s00330-012-2430-5. Epub 2012 Apr 1.

PMID:
22466514
2.

Comparison of T2(*) mapping with diffusion-weighted imaging in the characterization of low-grade vs intermediate-grade and high-grade prostate cancer.

Wu LM, Zhao ZZ, Chen XX, Lu Q, Suo ST, Liu Q, Hu J, Haccke EM, Xu JR.

Br J Radiol. 2016 Jul;89(1063):20151076. doi: 10.1259/bjr.20151076. Epub 2016 Apr 19.

3.

Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection--a multireader study.

Lim HK, Kim JK, Kim KA, Cho KS.

Radiology. 2009 Jan;250(1):145-51. doi: 10.1148/radiol.2501080207. Epub 2008 Nov 18.

PMID:
19017927
4.

Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness.

Vargas HA, Akin O, Franiel T, Mazaheri Y, Zheng J, Moskowitz C, Udo K, Eastham J, Hricak H.

Radiology. 2011 Jun;259(3):775-84. doi: 10.1148/radiol.11102066. Epub 2011 Mar 24.

5.

Prostate cancer: utility of diffusion-weighted imaging as a marker of side-specific risk of extracapsular extension.

Rosenkrantz AB, Chandarana H, Gilet A, Deng FM, Babb JS, Melamed J, Taneja SS.

J Magn Reson Imaging. 2013 Aug;38(2):312-9. doi: 10.1002/jmri.23972. Epub 2012 Dec 12.

PMID:
23238968
6.

Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined.

Chen M, Dang HD, Wang JY, Zhou C, Li SY, Wang WC, Zhao WF, Yang ZH, Zhong CY, Li GZ.

Acta Radiol. 2008 Jun;49(5):602-10. doi: 10.1080/02841850802004983.

PMID:
18568549
7.

The value of diffusion-weighted MRI for prostate cancer detection and localization.

Yağci AB, Ozari N, Aybek Z, Düzcan E.

Diagn Interv Radiol. 2011 Jun;17(2):130-4. doi: 10.4261/1305-3825.DIR.3399-10.1. Epub 2010 Aug 6.

8.
9.

Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.

Krishna S, McInnes M, Lim C, Lim R, Hakim SW, Flood TA, Schieda N.

AJR Am J Roentgenol. 2017 Dec;209(6):W365-W373. doi: 10.2214/AJR.17.17964. Epub 2017 Oct 5.

PMID:
28981356
10.

Prostate cancer: utility of fusion of T2-weighted and high b-value diffusion-weighted images for peripheral zone tumor detection and localization.

Rosenkrantz AB, Mannelli L, Kong X, Niver BE, Berkman DS, Babb JS, Melamed J, Taneja SS.

J Magn Reson Imaging. 2011 Jul;34(1):95-100. doi: 10.1002/jmri.22598.

PMID:
21698707
11.

Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI.

Kim CK, Park BK, Lee HM.

J Magn Reson Imaging. 2009 Feb;29(2):391-7. doi: 10.1002/jmri.21645.

PMID:
19161194
12.

Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging.

Panebianco V, Barchetti F, Sciarra A, Musio D, Forte V, Gentile V, Tombolini V, Catalano C.

Eur Radiol. 2013 Jun;23(6):1745-52. doi: 10.1007/s00330-013-2768-3. Epub 2013 Feb 2.

PMID:
23377546
13.

Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy?

Donati OF, Jung SI, Vargas HA, Gultekin DH, Zheng J, Moskowitz CS, Hricak H, Zelefsky MJ, Akin O.

Radiology. 2013 Aug;268(2):440-50. doi: 10.1148/radiol.13122149. Epub 2013 Mar 12.

PMID:
23481164
14.

Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology.

Selnæs KM, Heerschap A, Jensen LR, Tessem MB, Schweder GJ, Goa PE, Viset T, Angelsen A, Gribbestad IS.

Invest Radiol. 2012 Nov;47(11):624-33. doi: 10.1097/RLI.0b013e318263f0fd.

PMID:
23011187
15.

Anterior Prostate Cancer: Diagnostic Performance of T2-Weighted MRI and an Apparent Diffusion Coefficient Map.

Shinmoto H, Tamura C, Soga S, Okamura T, Horiguchi A, Asano T, Kaji T.

AJR Am J Roentgenol. 2015 Aug;205(2):W185-92. doi: 10.2214/AJR.14.13392.

PMID:
26204306
16.

Diffusion-weighted MR imaging for the evaluation of seminal vesicle invasion in prostate cancer: initial results.

Kim CK, Choi D, Park BK, Kwon GY, Lim HK.

J Magn Reson Imaging. 2008 Oct;28(4):963-9. doi: 10.1002/jmri.21531.

PMID:
18821631
17.

Prostate cancer vs. post-biopsy hemorrhage: diagnosis with T2- and diffusion-weighted imaging.

Rosenkrantz AB, Kopec M, Kong X, Melamed J, Dakwar G, Babb JS, Taouli B.

J Magn Reson Imaging. 2010 Jun;31(6):1387-94. doi: 10.1002/jmri.22172.

PMID:
20512891
18.

Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer.

Haider MA, van der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, Trachtenberg J.

AJR Am J Roentgenol. 2007 Aug;189(2):323-8.

PMID:
17646457
19.

Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer.

Gondo T, Hricak H, Sala E, Zheng J, Moskowitz CS, Bernstein M, Eastham JA, Vargas HA.

Eur Radiol. 2014 Dec;24(12):3161-70. doi: 10.1007/s00330-014-3367-7. Epub 2014 Aug 7.

PMID:
25100337
20.

Multiparametric MRI in detection and staging of prostate cancer.

Boesen L.

Dan Med J. 2017 Feb;64(2). pii: B5327. Review.

PMID:
28157066

Supplemental Content

Support Center